Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on Zeprumetostat PK in Healthy Chinese Adults
NCT04627129Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zeprumetostat in peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration at Day 11, Area Under the Curve from Time 0 to Last Measurable Concentration at Day 11 and 1 more. Started Jun 2020; status: completed.
02
Drugs
zeprumetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04627129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627129.